“Data now published in a major journal show that the Johnson & Johnson COVID-19 vaccine generated strong activity against SARS-CoV-2 for at least 8 months, including against variants of concern.
The results were published in a correspondence today in The New England Journal of Medicine, several weeks after Johnson & Johnson reported them in a news release and the researchers submitted them to a preprint server.
In the paper, Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and professor of medicine at Harvard Medical School, and colleagues report the 8-month durability of humoral and cellular immune responses among 20 people who received the Johnson & Johnson vaccine in one or two doses, and five people who received a placebo.
According to the study, they evaluated the antibody and T-cell responses of 10 people 8 months after they received a single dose of the vaccine, and 10 people 6 months after they received two doses. They also tested the performance of the vaccine against wild-type SARS-CoV-2 and the alpha (B.1.1.7), kappa (B.1.617.1), delta (B.1.617.2), gamma (P.1), epsilon (B.1.429) and beta (B.1.351) variants.”
Read more: https://www.nejm.org/doi/full/10.1056/NEJMc2108829
